摘要
目的探讨生长抑素联合生长激素治疗急性重症胰腺炎患者的临床效果。方法选取2019年6月至2021年4月本院收治的56例急性重症胰腺炎患者作为研究对象,随机分为联合用药组与单纯生长抑素组,每组28例。单纯生长抑素组在基础治疗基础上给予单纯生长抑素治疗,联合用药组在单纯生长抑素组基础上给予生长激素治疗,比较两组临床疗效、症状改善情况、炎症因子及免疫因子水平、并发症发生情况。结果联合用药组治疗总有效率高于单纯生长抑素组,差异有统计学意义(P<0.05)。联合用药组腹痛缓解时间、淀粉酶回归正常时间及住院时间均短于单纯生长抑素组,差异有统计学意义(P<0.05)。治疗后,两组CD4^(+)水平、CD4^(+)/CD8^(+)均高于治疗前,CD8^(+)水平均低于治疗前,且联合用药组CD4^(+)水平、CD4^(+)/CD8^(+)均高于单纯生长抑素组,CD8^(+)水平低于单纯生长抑素组,差异有统计学意义(P<0.05)。治疗后,两组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平均低于治疗前,且联合用药组低于单纯生长抑素组,差异有统计学意义(P<0.05)。联合用药组并发症发生率低于单纯生长抑素组,差异有统计学意义(P<0.05)。结论生长抑素联合生长激素治疗急性重症胰腺炎疗效显著,有利于改善患者免疫功能,缓解炎症状态,缩短腹痛症状缓解时间和住院时间,安全性较高,值得临床推广应用。
Objective To explore the clinical effect of somatostatin combined with growth hormone in the treatment of patients with acute severe pancreatitis.Methods 56 patients with acute severe pancreatitis admitted to our hospital from June 2019 to April 2021 were selected as the research subjects,and they were randomly divided into the combined medication group and the somatostatin alone group,with 28 cases in each group.The somatostatin group was treated with somatostatin alone on the basis of basic treatment,and the combined medication group was treated with growth hormone on the basis of the somatostatin alone group,the clinical efficacy,symptom improvement,levels of inflammatory factors and immune factors,and complications were compared between the two groups.Results The total effective rate in the combined medication group was higher than that in the somatostatin alone group,and the difference was statistically significant(P<0.05).The abdominal pain remission time,amylase returned to normal time and hospitalization time in the combined medication group were shorter than those in the somatostatin alone group,and the differences were statistically significant(P<0.05).After treatment,the CD4^(+)level and CD4^(+)/CD8^(+)in two groups were higher than those before treatment,and the levels of CD8^(+)were lower than those before treatment,and the CD4^(+)level and CD4^(+)/CD8^(+)in the combined medication group were higher than those in the somatostatin alone group,and CD8^(+)level was lower than that in the somatostatin alone group,the differences were statistically significant(P<0.05).After treatment,the levels of CRP,TNF-αand IL-6 in two groups were lower than those before treatment,and the combined medication group was lower than the somatostatin alone group,the differences were statistically significant(P<0.05).The incidence of complications in the combined medication group was lower than that in the somatostatin alone group,and the difference was statistically significant(P<0.05).Conclusion Somatostatin combined with
作者
林樊
曹百一
黄岩
LIN Fan;CAO Baiyi;HUANG Yan(Department of Pharmacy,Liaoyang Hospital of Traditional Chinese Medicine,Liaoyang,Liaoning,111000,China)
出处
《当代医学》
2023年第8期30-34,共5页
Contemporary Medicine
关键词
急性重症胰腺炎
生长抑素
生长激素
炎症因子
免疫因子
Acute severe pancreatitis
Somatostatin
Growth hormone
Inflammatory factors
immune factor
